The FDA rejected the heart drug serelaxin, the latest blow to a treatment Novartis hoped would be a cornerstone of a cardiovascular franchise.
India-based HCL Technologies has shown a skill for winning Big Pharma contracts, like the $500 million deal it inked with Merck in 2010. HCL has now added Novartis to its list of clients, with the Swiss pharma signing up to outsource its infrastructure management to the IT services company.
After nearly a year of fighting to protect the patent on its blockbuster leukemia drug Gleevec, Novartis has made peace with Indian drugmaker Sun Pharma, reaching a settlement that will keep Sun's generic version off the U.S. market until February 2016, Reuters reports. Novartis' U.S. patent expires in July 2015.
France's Servier has struck up a deal with Novartis to develop oncology drugs that invade tumors and lead them to self-destruct.
Novartis is facing yet another investigation in Japan. Little more than a month after a panel of Japanese lawyers uncovered serious misconduct during a trial of its leukemia drug, Tasigna, the Japanese government is probing whether the company broke the law by failing to report side effects of the product.
Given the eyebrow-raising cash component in Celgene's new deal with Nogra, we thought it would be fun to list the top 10 upfronts paid for experimental drugs, ranked simply according to the cash included in the upfront--no surer sign of what a company really thinks about the potential of an experimental therapy or portfolio.
First it was Italy, then it was France, and now the European Union is stepping up to take a serious look at how Swiss drugmakers Roche and Novartis have handled the marketing of their eye drug Lucentis.
Thanks to a steady flow of expensive new cancer therapies--and a public brouhaha over the cost of next-gen treatments for hepatitis C--drug prices are on center stage. We thought we'd look into the products whose prices have increased the most since 2007, to see how and why their prices are leaping.
Over the past few years, the bottom-line number on R&D spending among the big 10 pharma companies--about $70 billion--has remained about the same. But behind the steady collective figure lies...
Novartis says that a pivotal study of its long-acting version of Signifor demonstrated success in treating acromegaly, a condition in which excess levels of growth hormone causes body parts like the hands and feet and face to swell.